Recent Quotes (30 days)

You have no recent quotes
chg | %

Dechra Pharmaceuticals plc news

   Watch this stock
Showing stories 1 - 10 of about 75   

Articles published

DPH 1,172.00 +27.00 (2.36%)
price chart
Dechra Pharmaceuticals plc (DPH) Price Target Raised to GBX 1189 at Jefferies ...
Dechra Pharmaceuticals plc logo Dechra Pharmaceuticals plc (LON:DPH) had its target price increased by investment analysts at Jefferies Group from GBX 1,099 ($14.50) to GBX 1,189 ($15.68) in a research note issued on Thursday.
Jefferies International Indicates Potential 3.84% Increase In Shares Of ...  Fiscal Standard
Jefferies International Reiterates GBX 1189.00 Price Target On Dechra ...  Engelwood Daily
Dechra Pharmaceuticals PLC, Agrees Acquisition of US-based Putney, Inc for ...
Dechra Pharmaceuticals PLC (LSE: symbol DPH) announces the conditional acquisition of the entire share capital of Putney, Inc, a leading developer of generic companion animal pharmaceuticals in the US, based in Portland, Maine.
OP animal health parent leashes $200M acquisition  Kansas City Business Journal
How Analysts Feel About Dechra Pharmaceuticals plc After Today's Gap Up?
The stock of Dechra Pharmaceuticals plc (LON:DPH) gapped up by GBX 2 today and has GBX 1671.70 target or 46.00% above today's GBX 1145.00 share price.
Should you be buying AstraZeneca plc, Alliance Pharma plc and Dechra ...
One of the major concerns of investors in AstraZeneca (LSE: AZN) in recent years has been its ability to pay dividends. That's because it has been subjected to a patent cliff, where a number of key drugs have come off-patent and with the company ...
Should You Buy Dechra Pharmaceuticals plc, Enquest Plc & Cairn Energy PLC Today?
Pet medicines mammoth Dechra Pharmaceuticals (LSE: DPH) cheered the market with terrific half-year numbers in Monday business, propelling the stock 8% higher from the end of last week.
Dechra Pharmaceuticals PLC: Half-Yearly Financial Report 2016
"All our business units are performing well, we are in the process of launching several new products, our international expansion plans are progressing as expected and we have made two strategic acquisitions.
Are Genus plc And Dechra Pharmaceuticals plc Better Buys Than GlaxoSmithKline plc?
While shares in GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) have disappointed in the last year, it has not been the same story for a number of its pharmaceutical rivals. In fact, shares in Genus (LSE: GNS) and Dechra (LSE: DPH) have soared in the last 12 ...
Numis Securities Ltd Reaffirms "Add" Rating for Dechra Pharmaceuticals plc (DPH)
Dechra Pharmaceuticals plc logo Dechra Pharmaceuticals plc (LON:DPH)'s stock had its “add” rating restated by equities research analysts at Numis Securities Ltd in a report released on Friday.
Dechra Pharmaceuticals PLC (LON:DPH) Receives 'Add' Rating From ...  FTSE News
Dechra Pharmaceuticals PLC reiterated as Add By Numis  Fiscal Standard
Are GlaxoSmithKline plc, Dechra Pharmaceuticals plc & CareTech Holdings plc On ...
For example, Dechra (LSE: DPH) has been able to increase its earnings at a double-digit rate in each of the last three years, with it rising at an annualised rate of 23% during the period.
Dechra� Pharmaceuticals PLC (Dechra or the Group) : Trading Update
The Board of Dechra Pharmaceuticals PLC (LSE:DPH), issues the following unaudited Trading Update ahead of the Group's half-year financial results for the period ended 31 December 2015, which will be announced on Monday, 22 February 2016.